Endo (NDOI) Current Deferred Revenue : $0 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Endo Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Endo's current deferred revenue for the quarter that ended in Dec. 2024 was $0 Mil.

Endo Current Deferred Revenue Historical Data

The historical data trend for Endo's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo Current Deferred Revenue Chart

Endo Annual Data

Trend

Dec22

Dec23

Dec24

Current Deferred Revenue

Endo Quarterly Data
	Jun23	Sep23	Dec23	Apr24	Sep24	Dec24
Current Deferred Revenue	Get a 7-Day Free Trial			-	-	-	-	-

Endo Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Endo's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Endo Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo Inc (OTCPK:NDOI) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.endo.com

Endo Inc is a diversified pharmaceutical company. It has four reportable business segments: (1) Branded Pharmaceuticals, (2) Sterile Injectables, (3) Generic Pharmaceuticals and (4) International Pharmaceuticals. Branded Pharmaceuticals segment includes a variety of branded products in the therapeutic areas of urology, orthopedics, etc. Sterile Injectables segment consists of branded sterile injectable products such as ADRENALIN, VASOSTRICT and APLISOL, among others. Generic Pharmaceuticals segment includes a product portfolio including patches, solid oral extended-release products, etc. Key revenue is generated from International Pharmaceuticals segment includes a variety of specialty pharmaceutical products, including OTC products, sold outside the U.S.